Last verified: April 23, 2026 · FDA label, CMS Medicare Bridge, Lilly, Ro, and Sesame pricing confirmed

Eligibility Guide · April 2026

Who Qualifies for Foundayo? BMI Rules, Red Flags & the Access Paths That Actually Work (2026)

By The RX Index Editorial Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers. Last updated April 23, 2026

Who qualifies for Foundayo (orforglipron)? Adults 18 and older with a BMI of 30 or higher, or a BMI between 27 and 29.9 with at least one weight-related medical condition — most often hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or type 2 diabetes. That's the FDA-approved indication, and it's the rule every legitimate prescriber starts from.

But that's only gate one. Qualifying for Foundayo has three gates, and most pages stop at the first one:

1. The FDA label — the BMI + condition rule above.
2. Clinician safety screening — thyroid cancer history, MEN 2, pregnancy, another GLP-1, severe gastroparesis, and specific drug interactions can stop the prescription even if your BMI qualifies.
3. Payment access — commercial insurance, self-pay, and the Medicare GLP-1 Bridge each have their own rules. Medicare's criteria are stricter than the FDA's.

If any one of those three gates closes, Foundayo stops — no matter how well you clear the other two. Below we walk through each gate, show you the Foundayo Qualification & Access Matrix, and route you to the right next step.

Quick orientation — where do you land right now?

What we actually verified for this page

Claim category	Source	What we verified
FDA indication, contraindications, drug interactions	Foundayo U.S. Prescribing Information (Eli Lilly, 2026)	BMI + condition rule; contraindications; boxed warning; OC protocol; simvastatin 20 mg cap; CYP3A4/OATP1B dose cap
Self-pay pricing and Journey Program rules	LillyDirect Foundayo page and full terms	Dose-by-dose cash pricing, 45-day refill window
Medicare GLP-1 Bridge criteria, drugs, copay, dates	CMS.gov Medicare GLP-1 Bridge guidance (last modified March 10, 2026)	Three-tier eligibility rule; $50 copay; Bridge July 1, 2026–Dec 31, 2027 (18 months); BALANCE not launching Medicare Part D 2027
Ro Foundayo access and pricing	Ro Foundayo product and cost pages	Medication pricing, Ro Body membership structure, insurance concierge workflow
Sesame Care Foundayo access	Sesame Care weight loss program page	Program fee structure, provider-booked workflow, PA assistance

Last verified April 23, 2026. Re-checked monthly through the Foundayo launch window.

The FDA label: Foundayo's actual eligibility rule (gate one)

Foundayo is FDA-approved for adults with obesity (BMI ≥30) or adults who are overweight (BMI 27–29.9) with at least one weight-related medical condition, when used with a reduced-calorie diet and increased physical activity. That's the full eligibility rule on the public label — nothing about documented failed diet attempts, and nothing about a minimum duration of weight struggle.

Some pages add requirements that aren't in the label. “Documented previous weight-loss attempts” as a primary qualification is a payer requirement some insurance plans add during prior authorization — not an FDA rule. Mixing them up makes readers think they're disqualified when they're not.

Adults with a BMI of 30 or higher

If your BMI is 30 or higher, you meet the obesity criterion of the Foundayo indication. You don't need a comorbidity to qualify under the FDA label. The phase 3 ATTAIN-1 trial enrolled adults with obesity (BMI ≥30) or overweight (BMI 27 to <30) with at least one weight-related comorbid condition, and mean baseline BMI in that trial was 37 kg/m².

Adults with a BMI between 27 and 29.9 plus a weight-related condition

If your BMI is in the 27–29.9 range, the FDA label requires at least one weight-related comorbid condition. The pivotal trial populations that supported approval specifically enrolled people with hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease (ATTAIN-1) and type 2 diabetes (ATTAIN-2). Those five are the cleanest examples of qualifying conditions. Other conditions — PCOS, metabolic syndrome, fatty liver, prediabetes — are commonly accepted by clinicians as weight-related in daily practice, but are not explicitly named in the label text. Bring your full medical record to the consult; your prescriber decides based on current clinical practice.

Quick BMI check

BMI math: weight (lb) ÷ height (in)² × 703. Here's where common height/weight pairs land:

Under a BMI of 27? Foundayo isn't FDA-indicated for you.

If your BMI is below 27, Foundayo is not FDA-indicated for weight management. Off-label weight-loss prescribing below the indicated BMI is not standard practice and won't be covered by any insurer.

FDA-label eligibility vs. payer prior-auth rules (the distinction most pages get wrong)

The FDA label tells a prescriber when Foundayo can be prescribed. Your insurance plan's prior authorization criteria tell them when it will be covered. These are different things. You can fully qualify under the FDA label and still have your plan require:

• A minimum BMI higher than 30 (some plans set the floor at 35 or 40)
• Documentation of specific comorbidities with specific lab values
• Evidence of a structured lifestyle-modification attempt (“failed diet” language)
• Step therapy — trying a cheaper drug first

The conditions that count as “weight-related” for Foundayo

Foundayo's label requires at least one weight-related comorbid condition at BMI 27–29.9 but doesn't publish a consumer-facing exhaustive list. The conditions with the strongest support come from the pivotal ATTAIN-1 and ATTAIN-2 trials: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, and type 2 diabetes.

The five conditions with the strongest label and trial support

Conditions that sometimes count, depending on your prescriber and insurer

• ○Prediabetes — Not explicitly on Foundayo's named trial populations, but it is one of the qualifying conditions for the Medicare GLP-1 Bridge (when combined with BMI ≥27). If you have prediabetes and Medicare, this matters more than most pages flag.
• ○PCOS — Commonly accepted by clinicians as metabolically relevant and frequently listed in patient-facing eligibility explainers, but not in the label text. Bring records; let the prescriber decide.
• ○Fatty liver / MASLD — Clinically relevant, not explicitly label-named. Same category as PCOS.
• ○Metabolic syndrome — More a cluster diagnosis than a single condition; the components (hypertension, dyslipidemia, elevated fasting glucose) each stand on their own.

What to bring to the consult

• Your current height and weight (or a recent doctor-recorded BMI)
• A list of your diagnosed conditions with approximate dates
• Your current medication list (include hormonal contraceptives, statins, and any GLP-1 you're already on)
• Recent labs if you have them — HbA1c, lipid panel, basic metabolic panel
• Recent BP readings if hypertension is your qualifying condition
• Personal and family history of thyroid cancer
• Your insurance card (or a note that you're planning self-pay)

Who should not take Foundayo? Hard contraindications and stop-signs (gate two)

Foundayo's FDA label lists three formal contraindications: a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and a prior serious hypersensitivity reaction to orforglipron or any of its ingredients. The label also treats concomitant use with another GLP-1 as “not recommended,” and instructs discontinuation if pregnancy is confirmed.

Formal contraindications (hard stops on the FDA label)

• Personal or family history of medullary thyroid carcinoma (MTC)

  Foundayo carries a boxed warning for thyroid C-cell tumor risk — the same class warning every GLP-1 carries. Orforglipron, unlike peptide GLP-1s, didn't produce tumors in rodent studies because rodents aren't pharmacologically responsive to the drug. The human relevance hasn't been fully resolved, so the class warning stays.

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

  MEN 2 is a hereditary cancer syndrome strongly linked to medullary thyroid carcinoma, so the same hard stop applies.

• Prior serious hypersensitivity reaction to orforglipron

  Rare, but a hard contraindication if it applies to you.

Other stop-signs that aren't formal contraindications but will likely stop a prescription

• ⚠Already taking another GLP-1 — Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, Saxenda, or compounded semaglutide/tirzepatide. Concomitant use is not recommended. This is a switch-planning conversation with your current prescriber.
• ⚠Pregnant, trying to conceive, or breastfeeding — Foundayo must be discontinued when pregnancy is confirmed. Breastfeeding during treatment is not recommended.
• ⚠Under 18 — Safety and effectiveness have not been established in pediatric patients.

What can change the answer even if you qualify on paper

You can meet the BMI rule, clear the hard contraindications, and still be told Foundayo isn't your best first move because of a specific medication interaction or real-world fit issue. The biggest friction points are oral birth control, simvastatin above 20 mg, strong CYP3A4 inhibitors, severe gastroparesis or severe hepatic impairment, and daily-pill adherence.

Oral birth control pills

Foundayo delays gastric emptying, which can reduce the absorption of oral medications. The label recommends that patients on oral hormonal contraceptives switch to a non-oral method (IUD, implant, patch, ring, injection) or add a barrier method for 30 days after starting Foundayo and for 30 days after each dose increase. This isn't a contraindication — it's a protocol. Talk to your prescriber before starting.

Simvastatin — 20 mg daily cap

Foundayo inhibits OATP1B transporters, which increases simvastatin exposure and myopathy risk. The label caps simvastatin at 20 mg per day when co-administered with Foundayo. If you're on a higher dose — 40 or 80 mg is common — your prescriber may reduce your dose or switch you to a different statin before starting Foundayo.

Strong CYP3A4 inhibitors that also inhibit OATP1B

Certain medications (including some antifungals, HIV medications, and other drugs) inhibit both CYP3A4 and OATP1B pathways. The Foundayo label caps the maximum dose at 9 mg when these inhibitors are co-administered. A full medication review before starting is essential.

Severe gastroparesis

All GLP-1 medications slow gastric emptying. If you have severe gastroparesis (not mild or moderate — severe), GLP-1 therapy can worsen symptoms and is generally not recommended.

Severe hepatic impairment

Foundayo is not recommended in patients with severe hepatic impairment. Mild or moderate hepatic impairment doesn't carry the same restriction — this is a specialist-level conversation if severe liver disease is part of your history.

Insulin and sulfonylureas (hypoglycemia risk)

Foundayo can increase the hypoglycemia risk when combined with insulin or a sulfonylurea. Your prescriber may lower your insulin or sulfonylurea dose when starting Foundayo to manage the combined glucose-lowering effect.

Daily-pill adherence vs. a weekly injection

This isn't a medical contraindication — it's a fit question. Foundayo is a once-daily pill. Wegovy and Zepbound are once-weekly injections. If a daily pill is your preference because you hate needles, Foundayo is a strong match. If you know you'd forget a daily pill half the time, a weekly injection may fit your life better.

The Foundayo Qualification & Access Matrix

This matrix combines FDA-label eligibility, safety contraindications, Medicare GLP-1 Bridge criteria, and commercial/self-pay pricing into a single scenario map. Last verified April 23, 2026.

How to read it: find your access path first, then confirm your clinical profile fits that path's rules. Most readers focus on whether they meet the FDA label and are surprised later by a payer rule. The matrix puts both in view at once.

The honest gap table: who looks eligible but hits friction

Why qualifying medically isn't the same as getting a prescription or coverage

You can meet the FDA indication exactly and still hear “not the right fit” from a clinician or “not covered” from an insurer. Medical eligibility, clinician approval, and payment access are three separate decisions with different rules and different decision-makers.

Gate one: FDA-label eligibility

The FDA sets the baseline clinical rule. Meet the BMI + condition criteria and you're indication-eligible. This is the rule the prescriber starts from, but it's not the rule they end on.

Gate two: clinician safety and suitability screening

Your prescriber adds the safety screen — thyroid history, medication interactions, pregnancy status, prior GLP-1 use, gastroparesis, liver function, and a judgment call about whether Foundayo is the best first choice for you. This is where “I qualify on paper but she said Zepbound would be a better fit for me” happens. That's clinical judgment.

Gate three: payment access

• Commercial insurance: does the plan cover weight-management GLP-1s at all? The savings card may bring eligible patients to as low as $25/month, but only if the plan covers Foundayo.
• Self-pay: starts at $149/month for the starter dose through LillyDirect or Ro, scales by dose. Lilly's Journey Program requires a 45-day refill window to keep the $299 price on the highest two doses.
• Medicare: the GLP-1 Bridge runs July 1, 2026 through December 31, 2027 (18 months), charges a $50 flat copay for eligible beneficiaries, and uses three Bridge-specific tiers that are stricter than the FDA label. BALANCE did not launch for Medicare Part D in 2027.

Does Medicare cover Foundayo? (The Bridge rules are stricter than the FDA label.)

The CMS Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2026, and charges a $50 flat copay per monthly supply for eligible Medicare Part D beneficiaries. The Bridge uses a three-tier initiation-time BMI and condition rule that's stricter than the FDA label. The BALANCE Model launches January 1, 2027 as a broader Part D coverage pathway.

You qualify for the Medicare GLP-1 Bridge if you're at least 18 and you meet any one of these three tiers at the time you initiated GLP-1 therapy:

Three more things Medicare readers should know:

1. It's the BMI at initiation that counts — not your BMI on the day you file for the Bridge.
2. The Bridge uses a central prior authorization processor, not your Part D plan directly. Your doctor files the PA with the central processor; pharmacies bill through a Bridge-specific BIN/PCN.
3. Manufacturer savings cards don't apply to Medicare. Federal anti-kickback rules exclude government-insurance beneficiaries from commercial manufacturer coupons.

Is Foundayo on the Bridge drug list?

Why we're not routing Medicare readers to a commercial telehealth provider here

Most telehealth platforms that prescribe Foundayo — including Ro — do not currently coordinate coverage through Medicare or other government insurance programs. That's a standard limitation for commercial platforms. It's just the wrong first step for a Medicare-eligible reader.

The best way to get Foundayo online if you likely qualify

For commercially insured and self-pay adults who clearly qualify for Foundayo and want a streamlined FDA-approved-brand path, Ro is our primary recommendation, with Sesame Care as a strong secondary option for self-pay readers who want provider choice over integrated program support. Both carry Foundayo (orforglipron).

Why we put Ro first for Foundayo specifically

Ro is a U.S. telehealth platform that offers FDA-approved GLP-1 medications — including Foundayo, the Wegovy pill, the Wegovy pen, the Zepbound pen, and the Zepbound KwikPen — matches LillyDirect pricing on the medication itself, and runs an insurance concierge that submits prior authorization paperwork on your behalf.

• ○You submit your medical history, height/weight, and goals. A Ro-affiliated provider reviews your file and decides whether Foundayo is clinically appropriate. If you're using insurance, Ro's insurance concierge checks your benefits and files the PA for you. Ro states this process typically takes about 2–3 weeks end-to-end when insurance is involved.
• ○If insurance is denied, your Ro provider can suggest an FDA-approved cash-pay alternative rather than leaving you stranded.
• ○If you're paying cash, Ro states medication ships to your door and you can take your first dose in under a week.

When Sesame Care is actually the better pick

Sesame Care is a telehealth marketplace where you book a licensed clinician directly, pay for the visit, and get a Foundayo prescription sent to the pharmacy of your choice. It's strong for:

• ○Self-pay readers who want the lowest program fee
• ○Readers who want to choose their own clinician rather than being auto-matched
• ○Readers comparing multiple FDA-approved GLP-1s (Foundayo, Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda) in a single marketplace

The comparison at a glance

What Foundayo actually costs after you qualify

Foundayo's cash price is $149/month at the 0.8 mg starter dose and scales up to $349/month at the highest doses — unless you stay in the 45-day refill window of Lilly's Journey Program, which keeps the 14.5 mg and 17.2 mg doses at $299. Eligible commercially insured patients can pay as low as $25/month with the Foundayo savings card. Eligible Medicare Part D beneficiaries will pay a $50 flat copay starting July 1, 2026.

LillyDirect cash-pay pricing by dose

The Journey Program: if you miss the 45-day refill window on the two highest doses, you lose the $299 price and pay $349 the following month.

Commercial insurance with the Foundayo savings card

If your commercial plan covers Foundayo, the Foundayo Savings Card brings your copay as low as $25/month for eligible patients — up to $100 off a one-month fill, $200 off a two-month fill, or $300 off a three-month fill, up to 10 fills per calendar year. Commercial insurance only — government insurance beneficiaries are excluded from the savings card per federal anti-kickback rules.

Ro's total monthly cost

• ○Medication: $149–$349 by dose
• ○Ro Body membership: $39 first month, then $149/month ongoing, or $74/month annual plan
• ○First-time user at 0.8 mg starter: about $188 all-in
• ○Ongoing at 5.5 mg on annual plan: about $373 all-in

Sesame Care's total monthly cost

• ○Program fee: $59/month annual or $99/month month-to-month
• ○Starter dose on annual plan: about $208/month all-in
• ○At 5.5 mg on annual plan: about $358/month all-in

Medicare GLP-1 Bridge copay

$50 flat copay per monthly supply for eligible Medicare Part D beneficiaries — confirmed by CMS for the Bridge's operating period of July 1, 2026 through December 31, 2027 (18 months; BALANCE not launching Medicare Part D 2027). This copay does not change by dose. CMS added Foundayo to the Bridge drug list on April 6, 2026, so Foundayo is covered under the Bridge alongside Wegovy and Zepbound KwikPen for eligible beneficiaries.

Frequently asked questions about qualifying for Foundayo